Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago.
Join us at the poster session on June 3rd at 9am CDT.
Learn more: https://t.co/9RqPYL2fBx
We are excited to announce our commercial manufacturing collaboration with @BactheraAG for SER-109, an investigational microbiome therapeutic for recurrent #Cdiff infection. Learn more: https://t.co/0kPCTLEsuP
America’s coronavirus outbreak is playing out in two parts: containment in most of the earliest-hit states, and surging infections elsewhere https://t.co/09nKhpHDqn